Origin and In-Office Treatment of Retrograde Cricopharyngeus Dysfunction.
Abstract
[IMPORTANCE] Retrograde cricopharyngeus dysfunction (R-CPD) is an emerging disorder associated with disabling symptoms. The origin of R-CPD remains unknown.
[OBJECTIVE] To investigate the development of symptoms, diagnosis approach, and therapeutic outcomes of R-CPD in patients treated with in-office botulinum toxin injection (BTI) into the cricopharyngeus.
[DESIGN, SETTING, AND PARTICIPANTS] This was a case series including patients with R-CPD who were consecutively and prospectively recruited from April 2022 to May 2024 in an academic hospital. Semistructured interviews were conducted to collect and analyze data on each patient's clinical history, potential causes or factors associated with R-CPD development, diagnostic approaches, and symptom presentation.
[INTERVENTION] Clinic-based (in-office) BTI into the cricopharyngeus.
[OUTCOMES AND MEASURES] Associations with laryngopharyngeal reflux disease, patients' Reflux Symptom Score-12 (RSS-12), and BTI effectiveness, revisions, and complications were evaluated.
[RESULTS] The case series comprised 106 patients with R-CPD treated with BTI (52 females [49.1%] and 54 males [51.9%]). Their mean (SD) age at symptom onset was 13.6 (7.7) years, and at diagnosis, 30.4 (6.4) years. Sixty-eight patients (64.2%) had potential congenital R-CPD, according to the parents' testimonies. A family history was reported in 18 of 62 cases (29.0%). In 105 cases (99.1%), patients made the diagnosis themselves despite medical consultations (n = 162), empirical treatments (n = 113), and additional examinations (n = 92). The cumulative success rate of BTI was 90.6% (96 of 106 patients). In 26 cases (24.5%), additional injections were administered to address the symptoms. Family history of R-CPD was a negative predictor of single-BTI success. Dysphagia was the primary adverse effect occurring after 89 of 126 BTIs (70.6%) and lasted a mean (SD) of 16.3 (12.0) days. In 10 cases, operating-room BTI was administered after primary in-office BTI.
[CONCLUSIONS AND RELEVANCE] R-CPD is an emerging and poorly known disorder associated with high rates of ineffective consultations, additional examinations, and self-diagnosis by patients. In-office BTI was associated with a high rate of partial or total symptom relief and long-term effectiveness.
[OBJECTIVE] To investigate the development of symptoms, diagnosis approach, and therapeutic outcomes of R-CPD in patients treated with in-office botulinum toxin injection (BTI) into the cricopharyngeus.
[DESIGN, SETTING, AND PARTICIPANTS] This was a case series including patients with R-CPD who were consecutively and prospectively recruited from April 2022 to May 2024 in an academic hospital. Semistructured interviews were conducted to collect and analyze data on each patient's clinical history, potential causes or factors associated with R-CPD development, diagnostic approaches, and symptom presentation.
[INTERVENTION] Clinic-based (in-office) BTI into the cricopharyngeus.
[OUTCOMES AND MEASURES] Associations with laryngopharyngeal reflux disease, patients' Reflux Symptom Score-12 (RSS-12), and BTI effectiveness, revisions, and complications were evaluated.
[RESULTS] The case series comprised 106 patients with R-CPD treated with BTI (52 females [49.1%] and 54 males [51.9%]). Their mean (SD) age at symptom onset was 13.6 (7.7) years, and at diagnosis, 30.4 (6.4) years. Sixty-eight patients (64.2%) had potential congenital R-CPD, according to the parents' testimonies. A family history was reported in 18 of 62 cases (29.0%). In 105 cases (99.1%), patients made the diagnosis themselves despite medical consultations (n = 162), empirical treatments (n = 113), and additional examinations (n = 92). The cumulative success rate of BTI was 90.6% (96 of 106 patients). In 26 cases (24.5%), additional injections were administered to address the symptoms. Family history of R-CPD was a negative predictor of single-BTI success. Dysphagia was the primary adverse effect occurring after 89 of 126 BTIs (70.6%) and lasted a mean (SD) of 16.3 (12.0) days. In 10 cases, operating-room BTI was administered after primary in-office BTI.
[CONCLUSIONS AND RELEVANCE] R-CPD is an emerging and poorly known disorder associated with high rates of ineffective consultations, additional examinations, and self-diagnosis by patients. In-office BTI was associated with a high rate of partial or total symptom relief and long-term effectiveness.
추출된 의학 개체 (NER)
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 1 | |
| 해부 | BTI
→ botulinum toxin injection
|
scispacy | 1 | ||
| 합병증 | Cricopharyngeus
|
scispacy | 1 | ||
| 합병증 | laryngopharyngeal reflux
|
scispacy | 1 | ||
| 약물 | BTI
→ botulinum toxin injection
|
C1321035
Injection of botulinum toxin
|
scispacy | 1 | |
| 약물 | BTIs
|
scispacy | 1 | ||
| 약물 | [IMPORTANCE] Retrograde
|
scispacy | 1 | ||
| 약물 | [OBJECTIVE]
|
scispacy | 1 | ||
| 약물 | [DESIGN
|
scispacy | 1 | ||
| 약물 | [CONCLUSIONS AND
|
scispacy | 1 | ||
| 질환 | Retrograde cricopharyngeus dysfunction
|
scispacy | 1 | ||
| 질환 | laryngopharyngeal reflux disease
|
C1168250
Laryngopharyngeal Reflux
|
scispacy | 1 | |
| 질환 | Dysphagia
|
C0011168
Deglutition Disorders
|
scispacy | 1 | |
| 질환 | In-office BTI
|
scispacy | 1 | ||
| 기타 | cricopharyngeus
|
scispacy | 1 | ||
| 기타 | R-CPD
→ Retrograde cricopharyngeus dysfunction
|
scispacy | 1 | ||
| 기타 | patients
|
scispacy | 1 | ||
| 기타 | patient
|
scispacy | 1 |
MeSH Terms
Humans; Female; Male; Middle Aged; Adult; Prospective Studies; Aged; Pharyngeal Muscles; Deglutition Disorders; Treatment Outcome; Botulinum Toxins; Botulinum Toxins, Type A
🔗 함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
관련 논문
- Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.
- Comparative efficacy of intralesional therapies for keloid scars: a network meta-analysis.
- Adverse neurological events following botulinum toxin type A: A case series of post-injection seizures and paralysis.
- Decreased utilization of component separation techniques over time in complex abdominal wall reconstruction following introduction of preoperative botulinum toxin A.
- Current Perspectives on Pectoralis Minor Syndrome: A Narrative Review.